OMCL
Omnicell, Inc.NASDAQHealthcare$34.15+0.62%ClosedMarket Cap: $1.55B
As of 2026-04-06
Valuation
P/E (TTM)
756.16
PEG
—
P/B
1.25
P/S
1.31
EV/EBITDA
17.02
DCF Value
$36.43
FCF Yield
5.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
42.5%
Operating Margin
0.4%
Net Margin
0.2%
ROE
0.2%
ROA
0.2%
ROIC
0.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $314.0M | 41.5% | $415.0K | $-2.0M | $-0.05 | — |
| FY 2025 | $1.18B | 42.5% | $5.2M | $2.1M | $0.04 | — |
| Q3 2025 | $310.6M | 43.3% | $8.2M | $5.5M | $0.12 | — |
| Q2 2025 | $290.6M | 43.9% | $8.1M | $5.6M | $0.12 | — |
| Q1 2025 | $269.7M | 41.1% | $-11.6M | $-7.0M | $-0.15 | — |
| Q4 2024 | $306.9M | 46.6% | $13.8M | $15.8M | $0.34 | — |
| FY 2024 | $1.11B | 42.3% | $337.0K | $12.5M | $0.27 | — |
| Q3 2024 | $282.4M | 43.5% | $7.2M | $8.6M | $0.19 | — |
| Q2 2024 | $276.8M | 41.3% | $3.2M | $3.7M | $0.08 | — |
| Q1 2024 | $246.2M | 38.7% | $-18.7M | $-15.7M | $-0.34 | — |
| Q4 2023 | $258.8M | 40.7% | $-23.4M | $-14.4M | $-0.32 | — |
| FY 2023 | $1.15B | 43.6% | $-19.3M | $-20.4M | $-0.45 | — |